Giampaolo Merlini, M.D.

Dr. Giampaolo Merlini is the Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific Institute Policlinico San Matteo, University of Pavia, Italy. He is Professor of Clinical Biochemistry at the University of Pavia, and the President of the Post-Graduate Course in Medical Biotechnology. He is also the President of the International Society of Amyloidosis and Chairman of the Committee on Plasma Proteins, International Federation of Clinical Chemistry and Laboratory Medicine.

Dr. Merlini attended the Medical School of the University of Pavia as an alumnus of the Ghislieri College. After being awarded his medical degree, he trained in clinical and laboratory investigation of monoclonal gammapathies at Malmö General Hospital, Lund University, Sweden under the close guidance of Prof. Jan Waldenström. The encounter with Prof. Waldenström left a permanent imprint in Dr. Merlini’s scientific interests which have been focused since then on the investigation of the molecular mechanisms of diseases, and in particular on the biological activities of monoclonal proteins, and of the related clinical conditions. He further developed these lines of research at the Institute of Cancer Research, College of Physicians & Surgeons, Columbia University, New York under the expert direction of Prof. Elliott Osserman and in collaboration with the immunochemist Prof. Elvin Kabat. Prof. Osserman introduced him to the realm of systemic amyloidosis, and particularly to amyloidosis caused by misfolded monoclonal immunoglobulin light chains.

Dr. Merlini’s main research interests are the pathogenesis, natural history, diagnosis and treatment of monoclonal gammapathies, in particular immunoglobulin light chain amyloidosis. Recently his research has focused on the investigation of biomarkers for assessing prognosis and response to therapy and on the development of novel therapeutic agents and treatment designed in the light of advances in the understanding of the molecular mechanisms of these diseases. He is, and has been, principal investigator for several research projects in this field funded by the European Community and national research agencies. Dr. Merlini lectures widely and has written more than 300 articles, books, book chapters and reviews. Dr. Merlini’s contribution to the field of Waldenström’s macroglobulinemia spans from the investigation of the antibody activities of the monoclonal IgMs to the definition of the prognosis and treatment guidelines, and development of new therapeutic avenues. He was instrumental in establishing an international collaboration to define a new prognostic scoring system for Waldenström s macroglobulinemia.

Contact Info: Giampaolo Merlini, MD,  IRCCS Policlinico San Matteo Hospital,  University of Pavia,  Viale Golgi 19  27100 Pavia - PV, Italy  +39-0382-502490  +39-0382-502999 (fax),  Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Clinical Trials: https://clinicaltrials.gov/ct2/results?term=Merlini+Waldenstrom%27s